Merck MRK

  1. All
  2. Commentary
  3. Stock Reports
  4. Video Reports
  5. Fund Reports
  6. ETF Reports
  7. Headlines
    1. New Morningstar Analyst Report for GlaxoSmithKline PLC

      Stock Reports

      Thu, 21 Aug 2014

      similar benefits as Glaxo's key drugs.Glaxo's key vaccines Cervarix and Synflorix lost the first-mover advantage to Merck and Pfizer, respectively. Glaxo's next-generation respiratory drugs should help mitigate both branded and generic

    2. Merck : No Real Upside Catalysts On The Horizon

      Headlines

      Tue, 19 Aug 2014

      By Seeking Early Retirement : This article refers to the German Merck KGaA (OTC: MKGAF ). The more well known U.S. Merck & Co. (NYSE: MRK ) used to be part of Merck in the past, but has been expropriated during the First World War

    3. Oncothyreon -9.4% AH; tecemotide study fails to meet endpoints

      Headlines

      Mon, 18 Aug 2014

      Merck has informed Oncothyreon (NASDAQ: ONTY ) a randomized Phase 1/2 study of ..... progression free survival, time to progression or time to failure)." Merck has advised Oncothyreon it will "recommend that the investigational treatment

    4. Update: Opexa Q2 Earnings - Stock Down, But Buyout Thesis Remains Intact

      Headlines

      Fri, 15 Aug 2014

      in patients with Secondary Progressive Multiple Sclerosis (SPMS). I also argued that Merck Serono, the biopharmaceutical division of Merck (NYSE: MRK ), which has option and licensing rights to Tcelna, could acquire Opexa at a substantial

    5. UPDATE 2-U.S. FDA approves Merck insomnia drug

      Headlines

      Wed, 13 Aug 2014

      WASHINGTON, Aug 13 (Reuters) - The U.S. Food and Drug Administration said on Wednesday it has approved a new insomnia drug made by Merck & Co.

    6. Merck KGaA's (MKGAY) CEO Karl-Ludwig Kley on Q2 2014 Results - Earnings Call Transcript

      Headlines

      Wed, 13 Aug 2014

      Merck KGaA ADR ( OTCPK:MKGAY ) Q2 2014 Results ..... Dear, ladies and gentlemen, welcome to the Merck investor and analyst conference call on second ..... Constantin Fest, Head of Investor Relations at Merck , and I am very happy Complete Story »

    7. U.S. FDA approves Merck insomnia drug

      Headlines

      Wed, 13 Aug 2014

      WASHINGTON, Aug 13 (Reuters) - The U.S. Food and Drug Administration said on Wednesday it has approved a new insomnia drug made by Merck & Co..

    8. Merck insomnia drug cleared for sale in the U.S.

      Headlines

      Wed, 13 Aug 2014

      The FDA approves Merck 's ( MRK +1.3% ) Belsomra ( suvoexant ) tablets for the treatment of insomnia. Suvoexant is the first orexin receptor antagonist cleared

    9. New Morningstar Analyst Report for Merck KGaA

      Stock Reports

      Wed, 13 Aug 2014

      Merck 's internal research and development has ..... a major threat from generic competition. Merck 's restructured and more focused R&D programs ..... should yield increased productivity. We give Merck KGaA a Standard Stewardship Rating. Since

    10. Merck KGaA Posts In-Line 2Q as AZ Acquisition Helps Offset Rebif Declines

      Commentary

      Wed, 13 Aug 2014

      Merck KGaA reported second-quarter results that ..... our fair value estimate or moat ratings. Merck posted organic growth across all four business ..... 3% and Europe grew less than 1%. While Merck should continue to benefit from market growth

    « Prev12345Next »
    Content Partners